Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo

Leukemia Research

Volumn 36, Issue 3, 2012, Pages 363-368

  Sun, Luhong ^a   Zhang, Liang ^a   Qian, Jianfei ^a   Yang, Jing ^a   Yi, Qing ^a   Dong, Wenli ^a   Wang, Michael ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Atiprimod; Bortezomib; Combination therapy; Mantle cell lymphoma

Indexed keywords

APOPTOSIS INDUCING FACTOR; ATIPRIMOD; BORTEZOMIB; CASPASE 3; CASPASE 8; CASPASE 9; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MANTLE CELL LYMPHOMA; MONOTHERAPY; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SURVIVAL TIME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS INDUCING FACTOR; BLOTTING, WESTERN; BORONIC ACIDS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOMA, MANTLE-CELL; MALE; MICE; MICE, INBRED NOD; MICE, SCID; PYRAZINES; SPIRO COMPOUNDS; SURVIVAL RATE;

EID: 84855980463     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.09.014     Document Type: Article

References (28)

1. Wang M., Sun L., Qian J., Han X., Zhang L., Lin P., et al. D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy. Leukemia 2009, 23:1320-1328.
2. Hess G., Herbrecht R., Romaguera J., Verhoef G., Crump M., Gisselbrecht C., et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009, 27:3822-3829.
3. Argatoff L.H., Connors J.M., Klasa R.J., Horsman D.E., Gascoyne R.D. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 1997, 89:2067-2078.
4. Wang M., Zhang L., Han X., Yang J., Qian J., Hong S., et al. A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma. Clin Cancer Res 2008, 14:2154-2160.
5. Ruan J., Coleman M., Leonard J.P. Management of relapsed mantle cell lymphoma: still a treatment challenge. Oncology (Williston Park) 2009, 23:683-690.
6. Neri P., Tassone P., Shammas M., Yasui H., Schipani E., Batchu R.B., et al. Biological pathways and in vivo antitumor activity induced by atiprimod in myeloma. Leukemia 2007, 21:2519-2526.
7. Shailubhai K. Atiprimod: a multi-functional drug candidate for myeloid and other malignancies. Leuk Res 2007, 31:9-10.
8. Wang M., Talpaz M., Jagannath S., Chanan-Khan A.A., Alexanian R., Weber D.M., et al. A phase I, multi-center, dose escalation study of atiprimod in patients with refractory or relapsed multiple myeloma (MM). ASH Annu Meet Abstr 2005, 106:111.
9. Perez-Galan P., Roue G., Villamor N., Montserrat E., Campo E., Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006, 107:257-264.
10. Rajkumar S.V., Richardson P.G., Hideshima T., Anderson K.C. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005, 23:630-639.
11. Kane R.C., Dagher R., Farrell A., Ko C.W., Sridhara R., Justice R., et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 2007, 13:5291-5292.
12. Fisher R.I., Bernstein S.H., Kahl B.S., Djulbegovic B., Robertson M.J., de Vos S., et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006, 24:4867-4874.
13. Wang M., Zhang L., Han X., Yang J., Qian J., Hong S., et al. Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways. Blood 2007, 109:5455-5462.
14. Williams M.E., Dreyling M., Winter J., Muneer S., Leonard J.P. Management of mantle cell lymphoma: key challenges and next steps. Clin Lymphoma Myeloma Leuk 2010, 10:336-346.
15. Romaguera J.E., Fayad L., Rodriguez M.A., Broglio K.R., Hagemeister F.B., Pro B., et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005, 23:7013-7023.
16. O'Connor O.A., Wright J., Moskowitz C., Muzzy J., MacGregor-Cortelli B., Stubblefield M., et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005, 23:676-684.
17. Weigert O., Pastore A., Rieken M., Lang N., Hiddemann W., Dreyling M. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia 2007, 21:524-528.
18. Belch A., Kouroukis C.T., Crump M., Sehn L., Gascoyne R.D., Klasa R., et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 2007, 18:116-121.
19. Goy A., Kahl B. Mantle cell lymphoma: the promise of new treatment options. Crit Rev Oncol Hematol 2010, (December 16). [Epub ahead of print].
20. Corso A., Mangiacavalli S., Varettoni M., Pascutto C., Zappasodi P., Lazzarino M. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients. Leuk Res 2010, 34:471-474.
21. Goy A., Younes A., McLaughlin P., Pro B., Romaguera J.E., Hagemeister F., et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005, 23:667-675.
22. Hancock W.W., Schmidbauer G., Badger A.M., Kupiec-Weglinski J.W. SK&F 105685 suppresses allogenetically induced mononuclear and endothelial cell activation and cytokine production and prolongs rat cardiac allograft survival. Transplant Proc 1992, 24:231-232.
23. Albrightson-Winslow C.R., Brickson B., King A., Olivera D., Short B., Saunders C., et al. Beneficial effects of long-term treatment with SK&F 105685 in murine lupus nephritis. J Pharmacol Exp Ther 1990, 255:382-387.
24. Hamasaki M., Hideshima T., Tassone P., Neri P., Ishitsuka K., Yasui H., et al. (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. Blood 2005, 105:4470-4476.
25. Choudhari S.R., Khan M.A., Harris G., Picker D., Jacob G.S., Block T., et al. Deactivation of Akt and STAT3 signaling promotes apoptosis, inhibits proliferation, and enhances the sensitivity of hepatocellular carcinoma cells to an anticancer agent, atiprimod. Mol Cancer Ther 2007, 6:112-121.
26. Tassone P., Neri P., Carrasco D.R., Burger R., Goldmacher V.S., Fram R., et al. A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood 2005, 106:713-716.
27. Amit-Vazina M., Shishodia S., Harris D., Van Q., Wang M., Weber D., et al. Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. Br J Cancer 2005, 93:70-80.
28. Wang M., Han X.H., Zhang L., Yang J., Qian J.F., Shi Y.K., et al. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia 2008, 22:179-185.